GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2006

Laureate Pharma Will Continue to Manufacture Cytogen’s ProstaScint

  • Laureate Pharma renewed its agreement with Cytogen for the cGMP manufacture of ProstaScint®, Cytogen's Mab immunoconjugate that is used for imaging in patients diagnosed with prostate cancer.

    Under the agreement, Laureate will provide cGMP protein production and purification, conjugation of Cytogen's linker chelator, and aseptic filling services to support Cytogen's commercial ProstaScint requirements.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »